Mary Brainerd - Stryker Independent Director

SYK Stock  USD 357.87  0.84  0.23%   

Director

Ms. Mary K. Brainerd is Independent Director of the company. She is a former President and Chief Executive Officer of HealthPartners, the largest, consumergoverned, nonprofit health care organization in the United States, which she led from 2002 to May 2017. Prior to joining HealthPartners in 1992, she held various executive roles with Blue Cross and Blue Shield of Minnesota from 1984 to 1992. She also serves as a director of Bremer Bank and Securian Financial, a financial services company headquartered in Minneapolis. Ms. Brainerds extensive experience surrounding both health care delivery and insurance enable her to provide unique and invaluable insight to our Board discussions, particularly in light of the evolving landscape in the health care delivery and payer markets. since 2017.
Age 67
Tenure 7 years
Address 1941 Stryker Way, Portage, MI, United States, 49002
Phone269 385 2600
Webhttps://www.stryker.com
Brainerd received a B.A. from the University of Minnesota and a M.B.A. from the University of St. Thomas. She previously served on the boards of Possis Medical, Inc. and SurModics, Inc. and is one of the founding chief executive officers and the former chair of the Itasca Project, a group of 40 government, civic and business leaders addressing issues that impact longterm economic growth, including jobs, education, transportation and economic disparities, in the MinneapolisSt. Paul region.

Stryker Management Efficiency

The company has Return on Asset of 0.0687 % which means that on every $100 spent on assets, it made $0.0687 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1798 %, implying that it generated $0.1798 on every 100 dollars invested. Stryker's management efficiency ratios could be used to measure how well Stryker manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is expected to rise to 0.21 this year. Return On Assets is expected to rise to 0.11 this year. At this time, Stryker's Total Current Liabilities is quite stable compared to the past year. Liabilities And Stockholders Equity is expected to rise to about 41.9 B this year, although the value of Non Current Liabilities Other will most likely fall to about 1.8 B.
The company has 12.99 B in debt with debt to equity (D/E) ratio of 0.88, which is OK given its current industry classification. Stryker has a current ratio of 1.96, which is typical for the industry and considered as normal. Debt can assist Stryker until it has trouble settling it off, either with new capital or with free cash flow. So, Stryker's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Stryker sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Stryker to invest in growth at high rates of return. When we think about Stryker's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Hope TaitzSummit Hotel Properties
57
John HughesEquinix
64
William LubyEquinix
58
William KacalUS Silica Holdings
72
Diane DurenUS Silica Holdings
61
Thomas BartlettEquinix
59
Peter BernardUS Silica Holdings
59
Daniel AvramovichUS Silica Holdings
62
Michael SticeUS Silica Holdings
58
Mehul PatelSummit Hotel Properties
45
Irving LyonsEquinix
68
Christopher PaisleyEquinix
65
Bonnie LindUS Silica Holdings
60
Bjorn HansonSummit Hotel Properties
69
Scott KriensEquinix
60
Gary HromadkoEquinix
65
Kenneth KaySummit Hotel Properties
66
Nanci CaldwellEquinix
60
Thomas StoreySummit Hotel Properties
64
Michael LawsonUS Silica Holdings
N/A
Stryker Corporation operates as a medical technology company. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan. Stryker Corp operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 46000 people. Stryker (SYK) is traded on New York Stock Exchange in USA. It is located in 1941 Stryker Way, Portage, MI, United States, 49002 and employs 52,000 people. Stryker is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Stryker Leadership Team

Elected by the shareholders, the Stryker's board of directors comprises two types of representatives: Stryker inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Stryker. The board's role is to monitor Stryker's management team and ensure that shareholders' interests are well served. Stryker's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Stryker's outside directors are responsible for providing unbiased perspectives on the board's policies.
Andrew Silvernail, Independent Director
Fink, Vice President Global Human Resources
Sherilyn McCoy, Independent Director
Lisa Tatum, Independent Director
Robert Cohen, CTO Replacement
Ronda Stryker, Independent Director
Preston Wells, Vice President - Investor Relations
Curtis Hall, Chief Legal Officer
Ramesh Subrahmanian, Advisor
Spencer Stiles, Group President Orthopaedics and Spine
Andrew Pierce, Group Neurotechnology
William Berry, Principal Accounting Officer, Vice President, Corporate Controller
Allan Golston, Lead Independent Director
Katherine Owen, Vice President - Strategy and Investor Relations
Graham Mclean, President Asia-Pacific
Louise Francesconi, Independent Director
Kevin Lobo, Chairman of the Board, President, Chief Executive Officer
Giovanni Caforio, Independent Director
Jason Beach, Vice Relations
Roch Doliveux, Independent Director
David Floyd, Group President of Orthopaedics
William Jellison, CFO and VP
Yin Becker, Vice President - Communications, Public Affairs and Corporate Marketing
M Fink, Chief Human Resource Officer, Vice President
Timothy Scannell, Group President of Medsurg and Neurotechnology
William Parfet, Non-Executive Independent Chairman of the Board
Robert Fletcher, Vice President Chief Legal Officer
Dean Bergy, VP and Corporate Secretary
Rajeev Suri, Independent Director
Alan Douville, Chief VP
Glenn Boehnlein, Chief Financial Officer, Vice President
J Pierce, Group President MedSurg and Neurotechnology
Viju Menon, Group President - Global Quality and Business Operations
Lonny Carpenter, Group President - Global Quality and Operations
Bijoy Sagar, Chief Digital Technology Officer, Vice President
Mary Brainerd, Independent Director
Srikant Datar, Independent Director
Michael Hutchinson, General Counsel
Bronwen Taylor, Vice President - Compliance and Risk Management
Howard Cox, Independent Director
Steven Benscoter, Vice President - Human Resources
Kathryn Fink, Chief Human Resource Officer, Vice President
Scott Bruder, Vice President Chief Medical and Scientific Officer

Stryker Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Stryker a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

When determining whether Stryker is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Stryker Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Stryker Stock. Highlighted below are key reports to facilitate an investment decision about Stryker Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stryker. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing.
For more information on how to buy Stryker Stock please use our How to buy in Stryker Stock guide.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Complementary Tools for Stryker Stock analysis

When running Stryker's price analysis, check to measure Stryker's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Stryker is operating at the current time. Most of Stryker's value examination focuses on studying past and present price action to predict the probability of Stryker's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Stryker's price. Additionally, you may evaluate how the addition of Stryker to your portfolios can decrease your overall portfolio volatility.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Commodity Directory
Find actively traded commodities issued by global exchanges
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Transaction History
View history of all your transactions and understand their impact on performance
Is Stryker's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stryker. If investors know Stryker will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Stryker listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1.027
Dividend Share
3.05
Earnings Share
8.25
Revenue Per Share
53.999
Quarterly Revenue Growth
0.118
The market value of Stryker is measured differently than its book value, which is the value of Stryker that is recorded on the company's balance sheet. Investors also form their own opinion of Stryker's value that differs from its market value or its book value, called intrinsic value, which is Stryker's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Stryker's market value can be influenced by many factors that don't directly affect Stryker's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Stryker's value and its price as these two are different measures arrived at by different means. Investors typically determine if Stryker is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stryker's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.